| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
- Ball, A., et al.
(författare)
-
Design, implementation and first measurements with the Medipix2-MXR detector at the Compact Muon Solenoid experiment
- 2011
-
Ingår i: Journal of Instrumentation. - 1748-0221. ; 6
-
Tidskriftsartikel (refereegranskat)abstract
- The Medipix detector is the first device dedicated to measuring mixed-field radiation in the CMS (Compact Muon Solenoid) experiment cavern and able to distinguish between different particle types. Medipix2-MXR chips bump bonded to silicon sensors with various neutron conversion layers developed by the IEAP CTU in Prague were successfully installed for the 2008 LHC start-up in the CMS experimental and services caverns to measure the flux of various particle types, in particular neutrons. They have operated almost continuously during the 2010 run period, and the results shown here are from the proton run between the beginning of July and the end of October 2010. Clear signals are seen and different particle types have been observed during regular LHC luminosity running, and an agreement in the measured flux is found with the simulations. These initial results are promising, and indicate that these devices have the potential for further and future LHC and high energy physics applications as radiation monitoring devices for mixed field environments, including neutron flux monitoring. Further extensions are foreseen in the near future to increase the performance of the detector and its coverage for monitoring in CMS.
|
|
| 14. |
|
|
| 15. |
- Gardner-Sood, P, et al.
(författare)
-
Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses : baseline data from the IMPaCT randomized controlled trial
- 2015
-
Ingår i: Psychological Medicine. - 1469-8978. ; 45:12, s. 29-2619
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The aims of the study were to determine the prevalence of cardiometabolic risk factors and establish the proportion of people with psychosis meeting criteria for the metabolic syndrome (MetS). The study also aimed to identify the key lifestyle behaviours associated with increased risk of the MetS and to investigate whether the MetS is associated with illness severity and degree of functional impairment.METHOD: Baseline data were collected as part of a large randomized controlled trial (IMPaCT RCT). The study took place within community mental health teams in five Mental Health NHS Trusts in urban and rural locations across England. A total of 450 randomly selected out-patients, aged 18-65 years, with an established psychotic illness were recruited. We ascertained the prevalence rates of cardiometabolic risk factors, illness severity and functional impairment and calculated rates of the MetS, using International Diabetes Federation (IDF) and National Cholesterol Education Program Third Adult Treatment Panel criteria.RESULTS: High rates of cardiometabolic risk factors were found. Nearly all women and most men had waist circumference exceeding the IDF threshold for central obesity. Half the sample was obese (body mass index ≥ 30 kg/m2) and a fifth met the criteria for type 2 diabetes mellitus. Females were more likely to be obese than males (61% v. 42%, p < 0.001). Of the 308 patients with complete laboratory measures, 57% (n = 175) met the IDF criteria for the MetS.CONCLUSIONS: In the UK, the prevalence of cardiometabolic risk factors in individuals with psychotic illnesses is much higher than that observed in national general population studies as well as in most international studies of patients with psychosis.
|
|
| 16. |
- Morgan, Ruth A., et al.
(författare)
-
Carbonyl reductase 1 catalyzes 20 beta-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity
- 2017
-
Ingår i: Scientific Reports. - : Nature Publishing Group. - 2045-2322. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- Carbonyl Reductase 1 (CBR1) is a ubiquitously expressed cytosolic enzyme important in exogenous drug metabolism but the physiological function of which is unknown. Here, we describe a role for CBR1 in metabolism of glucocorticoids. CBR1 catalyzes the NADPH-dependent production of 20 beta-dihydrocortisol (20 beta-DHF) from cortisol. CBR1 provides the major route of cortisol metabolism in horses and is up-regulated in adipose tissue in obesity in horses, humans and mice. We demonstrate that 20 beta-DHF is a weak endogenous agonist of the human glucocorticoid receptor (GR). Pharmacological inhibition of CBR1 in diet-induced obesity in mice results in more marked glucose intolerance with evidence for enhanced hepatic GR signaling. These findings suggest that CBR1 generating 20 beta-dihydrocortisol is a novel pathway modulating GR activation and providing enzymatic protection against excessive GR activation in obesity.
|
|
| 17. |
- Nygård, Magnus M., et al.
(författare)
-
Local order in high-entropy alloys and associated deuterides - a total scattering and Reverse Monte Carlo study
- 2020
-
Ingår i: Acta Materialia. - : PERGAMON-ELSEVIER SCIENCE LTD. - 1359-6454 .- 1873-2453. ; 199, s. 504-513
-
Tidskriftsartikel (refereegranskat)abstract
- Many of the materials properties of high-entropy alloys (HEAs), like increased hardness, reduced thermal and electrical conductivity, and interesting hydrogen storage properties, are proposed to be related to local lattice distortions of the crystal structure due to the significant size differences between the elements of the alloy. However, direct evidence of this effect is very limited in the literature, and it therefore remains a hypothesis. This work presents a detailed assessment of the local lattice distortion in three body-centered cubic (bcc) HEAs TiVNb, TiVZrNb and TiVZrNbHf with varying atomic size differences using total scattering measurements and Reverse Monte Carlo structure modelling. The analysis indicates that the amount of local lattice distortion in the alloys increases with the elemental size difference in the alloy. The amount of lattice distortion is relieved when dideuterides with CaF2-type structures (Fm (3) over barm) are formed from the bcc (Im (3) over barm) HEAs. Analyses of the local environments around the deuterium atoms reveal an interesting correlation between the valence-electron concentration (VEC) of the nearest-neighbour metals and the stability of tetrahedral interstices with respect to deuterium occupation. Moreover, there is a tendency towards Ti/Nb short-range order in TiVNbD5.7 where the mixing entropy is lowest. In TiVZrNbHfD10, about 6 % of the deuterium atoms are displaced from the tetrahedral interstices with smaller volumes to octahedral interstices.
|
|
| 18. |
- Bueken, Bart, et al.
(författare)
-
Gel-based morphological design of zirconium metal-organic frameworks
- 2017
-
Ingår i: Chemical Science. - : Royal Society of Chemistry (RSC). - 2041-6520 .- 2041-6539. ; 8:5, s. 3939-3948
-
Tidskriftsartikel (refereegranskat)abstract
- The ability of metal-organic frameworks (MOFs) to gelate under specific synthetic conditions opens up new opportunities in the preparation and shaping of hierarchically porous MOF monoliths, which could be directly implemented for catalytic and adsorptive applications. In this work, we present the first examples of xero-or aerogel monoliths consisting solely of nanoparticles of several prototypical Zr4+-based MOFs: UiO-66-X (X - H, NH2, NO2, (OH)(2)), UiO-67, MOF-801, MOF-808 and NU-1000. High reactant and water concentrations during synthesis were observed to induce the formation of gels, which were converted to monolithic materials by drying in air or supercritical CO2. Electron microscopy, combined with N-2 physisorption experiments, was used to show that irregular nanoparticle packing leads to pure MOF monoliths with hierarchical pore systems, featuring both intraparticle micropores and interparticle mesopores. Finally, UiO-66 gels were shaped into monolithic spheres of 600 mm diameter using an oil-drop method, creating promising candidates for packed-bed catalytic or adsorptive applications, where hierarchical pore systems can greatly mitigate mass transfer limitations.
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
- Jatuworapruk, Kanon, et al.
(författare)
-
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19 : Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
- 2022
-
Ingår i: ACR Open Rheumatology. - : John Wiley & Sons. - 2578-5745. ; 4:11, s. 948-953
-
Tidskriftsartikel (refereegranskat)abstract
- ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
|
|
| 22. |
- Keen, Sara C., et al.
(författare)
-
Non-native species change the tune of tundra soils : novel access to soundscapes of the Arctic earthworm invasion
- 2022
-
Ingår i: Science of the Total Environment. - : Elsevier. - 0048-9697 .- 1879-1026. ; 838
-
Tidskriftsartikel (refereegranskat)abstract
- Over the last decade, an increasing number of studies have used soundscapes to address diverse ecological questions. Sound represents one of the few sources of information capable of providing in situ insights into processes occurring within opaque soil matrices. To date, the use of soundscapes for soil macrofauna monitoring has been experimentally tested only in controlled laboratory environments. Here we assess the validity of laboratory predictions and explore the use of soil soundscape proxies for monitoring soil macrofauna (i.e., earthworm) activities in an outdoor context. In a common garden experiment in northern Sweden, we constructed outdoor mesocosm plots (N = 36) containing two different Arctic vegetation types (meadow and heath) and introduced earthworms to half of these plots. Earthworms substantially altered the ambient soil soundscape under both vegetation types, as measured by both traditional soundscape indices and frequency band power levels, although their acoustic impacts were expressed differently in heath versus meadow soils. While these findings support the as-of-yet untapped promise of using belowground soundscape analyses to monitor soil ecosystem health, direct acoustic emissions from earthworm activities appear to be an unlikely proxy for tracking worm activities at daily timescales. Instead, earthworms indirectly altered the soil soundscape by ‘re-engineering’ the soil matrix: an effect that was dependent on vegetation type. Our findings suggest that long-term (i.e., seasonal) earthworm activities in natural soil settings can likely be monitored indirectly via their impacts on soundscape measures and acoustic indices. Analyzing soil soundscapes may enable larger-scale monitoring of high-latitude soils and is directly applicable to the specific case of earthworm invasions within Arctic soils, which has recently been identified as a potential threat to the resilience of high-latitude ecosystems. Soil soundscapes could also offer a novel means to monitor soils and soil-plant-faunal interactions in situ across diverse pedogenic, agronomic, and ecological systems.
|
|
| 23. |
- Pignolo, Robert J., et al.
(författare)
-
Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)
- 2023
-
Ingår i: Journal of Bone and Mineral Research. - : John Wiley & Sons. - 0884-0431 .- 1523-4681. ; 38:3, s. 381-394
-
Tidskriftsartikel (refereegranskat)abstract
- Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, severely disabling genetic disorder of progressive heterotopic ossification (HO). The single-arm, open-label, phase 3 MOVE trial (NCT03312634) assessed efficacy and safety of palovarotene, a selective retinoic acid receptor gamma agonist, in patients with FOP. Findings were compared with FOP natural history study (NHS; NCT02322255) participants untreated beyond standard of care. Patients aged ≥4 years received palovarotene once daily (chronic: 5 mg; flare-up: 20 mg for 4 weeks, then 10 mg for ≥8 weeks; weight-adjusted if skeletally immature). The primary endpoint was annualized change in new HO volume versus NHS participants (by low-dose whole-body computed tomography [WBCT]), analyzed using a Bayesian compound Poisson model (BcPM) with square-root transformation. Twelve-month interim analyses met futility criteria; dosing was paused. An independent Data Monitoring Committee recommended trial continuation. Post hoc 18-month interim analyses utilized BcPM with square-root transformation and HO data collapsed to equalize MOVE and NHS visit schedules, BcPM without transformation, and weighted linear mixed-effects (wLME) models, alongside prespecified analysis. Safety was assessed throughout. Eighteen-month interim analyses included 97 MOVE and 101 NHS individuals with post-baseline WBCT. BcPM analyses without transformation showed 99.4% probability of any reduction in new HO with palovarotene versus NHS participants (with transformation: 65.4%). Mean annualized new HO volume was 60% lower in MOVE versus the NHS. wLME results were similar (54% reduction fitted; nominal p = 0.039). All palovarotene-treated patients reported ≥1 adverse event (AE); 97.0% reported ≥1 retinoid-associated AE; 29.3% reported ≥1 serious AE, including premature physeal closure (PPC)/epiphyseal disorder in 21/57 (36.8%) patients aged <14 years. Post hoc computational analyses using WBCT showed decreased vertebral bone mineral density, content, and strength, and increased vertebral fracture risk in palovarotene-treated patients. Thus, post hoc analyses showed evidence for efficacy of palovarotene in reducing new HO in FOP, but high risk of PPC in skeletally immature patients.
|
|
| 24. |
- Pignolo, Robert J., et al.
(författare)
-
The effects of palovarotene in patients with fibrodysplasia ossificans progressiva : a plain language summary
- 2023
-
Ingår i: Future Rare Diseases. - : Future Medicine. - 2399-5270 .- 2399-5262. ; 3:1
-
Forskningsöversikt (refereegranskat)abstract
- What is this summary about?This is a plain language summary of an article originally published in the Journal of Bone and Mineral Research. People with fibrodysplasia ossificans progressiva (FOP) become physically disabled over time as new bone forms in places where it is not usually found, such as in muscles and ligaments. Until recently, there were no treatments for FOP that had been proven through clinical trials; however, a drug called palovarotene has been tested in clinical trials and may be effective. Here, we describe the MOVE trial, which investigated how effectively palovarotene works, as well as its safety in treating patients with FOP.What were the results?Results from MOVE suggest that palovarotene may reduce extra bone formation outside the normal skeleton. Patients with FOP who took palovarotene formed less new bone than those who did not take palovarotene. The most common side effects involved the skin, and included dryness and irritation. Some children who were still growing when they took palovarotene had a side effect that resulted in the (normal) growth of their skeleton stopping too soon.What do the results of the trial mean?Palovarotene may be a useful treatment option for FOP. Patients, caregivers, and doctors would need to consider the benefits and risks of treatment with palovarotene, particularly with growing children.
|
|
